Infectex Ltd., a portfolio company of Maxwell Biotech Venture Fund (MBVF) today announced the successful completion of a Phase I clinical trial of an oral formulation of Q203 for the treatment of tuberculosis. The product is developed by Infectex in Russia/CIS under a license from Qurient Co. Ltd. (South Korea).
The trial was a single-center, open-label prospective clinical study to assess safety, tolerability and pharmacokinetics of ascending doses of Q203 in single use in healthy volunteers. A total of 30 healthy adult volunteers were randomized into 5 cohorts to receive one of five single ascending oral doses of Q203 (10, 30, 50, 100 – fasting and after meal consequently, and 200 mg). The stage of Q203 administration was followed by the observation period.
The study has proven Q203 to be safe and well tolerated across all doses tested. All treatment-related adverse effects were deviations of laboratory parameters and were mild. They resolved without intervention.
“Q203 is undergoing intensive phase 1 testing and demonstrates excellent results in all studies, including one that is completed by our partner Infectex”, — said Dr. Kiyean Nam, Chairman and Chief Executive Officer of Qurient Co.
“With growing importance of tuberculosis caused by multidrug-resistant and extensively drug resistant forms of M. tuberculosis, we are excited to make this significant step in clinical development of Q203”, said Dmitry Popov, Managing Partner of MBVF.
Q203 is an orally active small molecule drug candidate (imidazopyridine amide compound) that blocks Mycobacterium tuberculosis growth by inhibiting cytochrome bc1 complex, leading to the depletion of adenosine triphosphate (ATP) synthesis of M. tuberculosis.
Infectex (Moscow, Russia) is a biotechnology company founded in 2011 with the goal to develop and bring to the Russian market drugs for MDR-TB. Currently the company is developing two anti-TB drugs, SQ109 and Q203. Infectex is a resident company of Skolkovo Innovation Center.
Qurient Co., Ltd. (Seongnam, South Korea) engages in the development of novel therapeutics. The company’s pipelines products include Q203 drug for the treatment of Mycobacterium tuberculosis that is in phase I stage. The company was founded in 2008 and was formerly known as Quro Science Inc.
About Maxwell Biotech Venture Fund (MBVF)
Maxwell Biotech Venture Fund is the first Russian venture fund fully dedicated to investments in Life Sciences technologies. The fund has been created with participation of the Russian Venture Company. MBVF portfolio companies have nine innovative clinical stage drug candidates in development; four thereof are in late clinical stage of development.
+7 (495) 726-52-53